SKAN Group AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0013396012
CHF
48.40
-1.15 (-2.32%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About SKAN Group AG stock-summary
stock-summary
SKAN Group AG
Pharmaceuticals & Biotechnology
BV Holding AG is a Switzerland-based holding company of an equity investment group, engaged in the participation in enterprises in Switzerland and bordering countries. It concentrates on companies from the industry, micro and medical technology, processing and material technology, information technology and related services. Target enterprises are those being in special situations, such as management buy-out and buy-in, changes in shareholders’ structure, succession financing, as well as coming through growth or expansion phase. The Company acts as an entrepreneurial partner in the long term. Operational activities are delegated to the independent advisor BV Partners AG. BV Holding AG and BV Partners AG form the BVgroup. As of December 31, 2011, its investment portfolio included nine companies: Covalys BioSciences AG, E2E Technologies Ltd., Lonstroff Holding AG, Piexon AG, POLYDATA AG, SKAN Holding AG, Sphinx Werkzeuge AG, Ypsomed Holding AG and Ziemer Group AG.
Company Coordinates stock-summary
Company Details
Hofgut, Vordere Dorfgasse 12 , GUEMLIGEN None : 3073
stock-summary
Tel: 41 31 380185041 31 3801850
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Ernst Balmer
Chairman of the Board of Directors
Dr. Willy Michel
Vice Chairman of the Board of Directors
Dr. Rubino Mordasini
Member of the Board of Directors
Mr. Thomas Plattner
Member of the Board of Directors
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 1,088 Million ()

stock-summary
P/E

39.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

38.49%

stock-summary
Debt Equity

-1.53

stock-summary
Return on Equity

17.36%

stock-summary
Price to Book

6.14